VectorB2B-Drug Developing is a non-profit association created in 2019 that provides highly qualified services of drug discovery and development from the bench to bedside (B2B). Not only standard assays can be performed, but high added-value project design and innovative R&D solutions are available to customers. We act both as solution provider and solution enabler, meaning that the association provide original innovative assays not in the portfolio of conventional CROs or CMOs. This is possible because we incorporate knowledge and R&D from strong academic and biotech groups working in the forefront of the state of the art in biological drug/target discovery, development and evaluation. VectorB2B is an “one stop shop” for other companies and academia involved in biological Drug Discovery and Development. In terms of areas, VectorB2B is divided in Discovery, Toxicology, CMC and CRO. Our mission is to offer a unique solution of combined expertise that supports the development of health products from design, lead selection and optimization; to their production, characterization and formulation; and into studies to pre-and-clinical stages.